Pharmala Biotech Holdings (XCNQ:MDMA) EV-to-Revenue : 13.48 (As of Jun. 04, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pharmala Biotech Holdings's enterprise value is C$17.27 Mil. Pharmala Biotech Holdings's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 was C$1.28 Mil. Therefore, Pharmala Biotech Holdings's EV-to-Revenue for today is 13.48.

The historical rank and industry rank for Pharmala Biotech Holdings's EV-to-Revenue or its related term are showing as below:

XCNQ:MDMA' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.22 Med: 23.28 Max: 319.69
Current: 13.49

During the past 3 years, the highest EV-to-Revenue of Pharmala Biotech Holdings was 319.69. The lowest was 6.22. And the median was 23.28.

XCNQ:MDMA's EV-to-Revenue is ranked worse than
60.6% of 1038 companies
in the Biotechnology industry
Industry Median: 8.075 vs XCNQ:MDMA: 13.49

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-04), Pharmala Biotech Holdings's stock price is C$0.19. Pharmala Biotech Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.02. Therefore, Pharmala Biotech Holdings's PS Ratio for today is 12.67.

Pharmala Biotech Holdings EV-to-Revenue Historical Data

The historical data trend for Pharmala Biotech Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings EV-to-Revenue Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

EV-to-Revenue

42.28

35.71

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-Revenue	Get a 7-Day Free Trial							60.89	280.61	35.71	6.59	12.52

Competitive Comparison of Pharmala Biotech Holdings's EV-to-Revenue

For the Biotechnology subindustry, Pharmala Biotech Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's EV-to-Revenue falls into.

Pharmala Biotech Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pharmala Biotech Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	17.273	/	1.281
	=	13.48

Pharmala Biotech Holdings's current Enterprise Value is C$17.27 Mil.
Pharmala Biotech Holdings's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.28 Mil.

Pharmala Biotech Holdings (XCNQ:MDMA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pharmala Biotech Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.19	/	0.015
	=	12.67

Pharmala Biotech Holdings's share price for today is C$0.19.
Pharmala Biotech Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.02.

Pharmala Biotech Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

PMBHF:USA

Address

82 Richmond Street East, Toranto, ON, CAN, M5C 1P1

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines